

## Antivirals - Cytomegalovirus (CMV)

**Phone: 215-991-4300**
**Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:		Prescriber Name:	
HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

***Please answer the following questions and sign.***

Q1. Is the patient prescribed the Antiviral, CMV for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication?

 Yes

 No

Q2. Is the patient of an appropriate age for the requested drug according to Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

 Yes

 No

Q3. Is the patient prescribed a dose and duration of therapy that are consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

 Yes

 No

Q4. Does the patient have a contraindication to the requested medication?

 Yes

 No

Q5. Is this a request for Previmis (Ietermovir)?

## Antivirals - Cytomegalovirus (CMV)

**Phone: 215-991-4300**
**Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:	Prescriber Name:
<input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q6. Is Prevyms (letermovir) being prescribed by or in consultation with an appropriate specialist (i.e., hematologist/oncologist, infectious disease specialist, or transplant specialist)?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q7. For Prevyms (letermovir): Does the patient meet one of the following in accordance with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature: A) Is cytomegalovirus (CMV) seropositive? OR B) Is at a high risk of cytomegalovirus (CMV) reactivation?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q8. For Prevyms (letermovir) one of the following: A) Is prescribed letermovir for continuation of treatment upon inpatient discharge. B) Will initiate treatment with letermovir in the post-transplant period in accordance with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q9. For Livtency (maribavir): Is being prescribed by or in consultation with an appropriate specialist (i.e., hematologist/oncologist, infectious disease specialist, or transplant specialist)?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q10. For Livtency (maribavir): If currently taking ganciclovir or valganciclovir, will discontinue ganciclovir or valganciclovir prior to starting maribavir?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	
<p>Q11. For Livtency (maribavir) for treatment of post-transplant CMV infection/disease, one of the following: A) Is prescribed maribavir for continuation of treatment upon inpatient discharge? B) The patient has history of therapeutic failure of or a contraindication or an intolerance to at least one of the following (Ganciclovir, Valganciclovir, Cidofovir, Foscarnet)? C) Has culture and sensitivity results documenting that only maribavir will be effective?</p> <input type="checkbox"/> Yes <span style="margin-left: 200px;"><input type="checkbox"/> No</span>	

## Antivirals - Cytomegalovirus (CMV)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Member Name:

Prescriber Name:

Q12. For all other non-preferred Antivirals, CMV, one of the following: A) Has a history of therapeutic failure, contraindication to, or intolerance of the preferred cytomegalovirus (CMV) antiviral drugs for the patient's diagnosis or indication. B) Has culture and sensitivity results showing both of the following a) The beneficiary's infection is not susceptible to the preferred Antivirals, CMV? b) The beneficiary's infection is susceptible to the requested non-preferred Antiviral, CMV?

 Yes No

Q13. Additional Information:

\_\_\_\_\_  
Prescriber Signature\_\_\_\_\_  
Date

v2025